The multiparametric cardiac and kidney imaging data along with the extensive biomarker analyses of the EMPRESS‐MI trial will provide novel insights into the potential mechanisms of benefit of SGLT2 inhibition in high‐risk survivors of acute MI. Here, SLC5A2 is linked to myocardial infarction.